Review



oa sangon  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress oa sangon
    EVA1A deletion promotes the palmitoylation of CD36. (A to C) The palmitoylation levels of CD36 were assessed using the APE assay after treatment <t>with</t> <t>2-BP</t> (50 μM, 6 h) as indicated, with or without HA. The top band indicated the palmitoylated CD36 (PEG-CD36). Detection of palmitoylated CD36 in EVA1A-knockdown HepG2 and Huh7 cells, along with control cells (A). Detection of palmitoylated CD36 in EVA1A-overexpressed HepG2 and Huh7 cells or control cells (B). Detection of palmitoylated CD36 in live tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3) (C). Protein levels of palmitoylated CD36 were quantified in the right panels. (D to G) Relative mRNA levels of genes related to palmitoyl transferases (Z DHHC4 and Z DHHC5 ) and acyl-protein thioesterase 1 ( LYPLA1 ) in vitro (D and E) and in vivo (F and G). (H) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in EVA1A-knockdown or overexpressed HepG2 and Huh7 cells, after 6-h treatment with 400 μM OA or after being left untreated. (I) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in liver tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3). Their protein levels were quantified in the lower panels. * P < 0.05, **P < 0.01, ***P < 0.001. HA: NH 2 OH.
    Oa Sangon, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oa sangon/product/MedChemExpress
    Average 93 stars, based on 3 article reviews
    oa sangon - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "EVA1A Regulates Hepatic Lipid Homeostasis by Modulating CD36 Expression and Its Palmitoylation"

    Article Title: EVA1A Regulates Hepatic Lipid Homeostasis by Modulating CD36 Expression and Its Palmitoylation

    Journal: Research

    doi: 10.34133/research.1001

    EVA1A deletion promotes the palmitoylation of CD36. (A to C) The palmitoylation levels of CD36 were assessed using the APE assay after treatment with 2-BP (50 μM, 6 h) as indicated, with or without HA. The top band indicated the palmitoylated CD36 (PEG-CD36). Detection of palmitoylated CD36 in EVA1A-knockdown HepG2 and Huh7 cells, along with control cells (A). Detection of palmitoylated CD36 in EVA1A-overexpressed HepG2 and Huh7 cells or control cells (B). Detection of palmitoylated CD36 in live tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3) (C). Protein levels of palmitoylated CD36 were quantified in the right panels. (D to G) Relative mRNA levels of genes related to palmitoyl transferases (Z DHHC4 and Z DHHC5 ) and acyl-protein thioesterase 1 ( LYPLA1 ) in vitro (D and E) and in vivo (F and G). (H) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in EVA1A-knockdown or overexpressed HepG2 and Huh7 cells, after 6-h treatment with 400 μM OA or after being left untreated. (I) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in liver tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3). Their protein levels were quantified in the lower panels. * P < 0.05, **P < 0.01, ***P < 0.001. HA: NH 2 OH.
    Figure Legend Snippet: EVA1A deletion promotes the palmitoylation of CD36. (A to C) The palmitoylation levels of CD36 were assessed using the APE assay after treatment with 2-BP (50 μM, 6 h) as indicated, with or without HA. The top band indicated the palmitoylated CD36 (PEG-CD36). Detection of palmitoylated CD36 in EVA1A-knockdown HepG2 and Huh7 cells, along with control cells (A). Detection of palmitoylated CD36 in EVA1A-overexpressed HepG2 and Huh7 cells or control cells (B). Detection of palmitoylated CD36 in live tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3) (C). Protein levels of palmitoylated CD36 were quantified in the right panels. (D to G) Relative mRNA levels of genes related to palmitoyl transferases (Z DHHC4 and Z DHHC5 ) and acyl-protein thioesterase 1 ( LYPLA1 ) in vitro (D and E) and in vivo (F and G). (H) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in EVA1A-knockdown or overexpressed HepG2 and Huh7 cells, after 6-h treatment with 400 μM OA or after being left untreated. (I) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in liver tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3). Their protein levels were quantified in the lower panels. * P < 0.05, **P < 0.01, ***P < 0.001. HA: NH 2 OH.

    Techniques Used: Knockdown, Control, In Vitro, In Vivo, Western Blot

    Inhibition of CD36 palmitoylation attenuates EVA1A deficiency-induced fatty acid uptake and lipid droplet accumulation. (A and E) The EVA1A-knockdown HepG2 or Huh7 cells were transfected with empty vector (pcDNA3.1) or wt-CD36, or mut-CD36 plasmid for 24 h, which had been treated with 400 μM OA during the final 6 h, then were fixed and stained with BODIPY FL-C16 (A) or ORO (E). Scale bars: 20 μm. The fluorescence signal intensity of FL-C16 per cell was quantified by ImageJ. Values were means ± SDs ( n = 50). (B) Cellular NEFA levels in cells subjected to the treatment shown in (A). (C and G) The EVA1A-knockdown cells were co-treated with 50 μM 2-BP and 400 μM OA for 6 h, then were subjected to BODIPY FL-C16 staining (C) or ORO staining (G). Scale bars: 20 μm. (D) Cellular NEFA levels in cells subjected to the treatment shown in (C). (F) Cellular TG contents in cells treated as described in (A). (H) Cellular TG contents in cells treated as described in (C). * P < 0.05, **P < 0.01, ***P < 0.001.
    Figure Legend Snippet: Inhibition of CD36 palmitoylation attenuates EVA1A deficiency-induced fatty acid uptake and lipid droplet accumulation. (A and E) The EVA1A-knockdown HepG2 or Huh7 cells were transfected with empty vector (pcDNA3.1) or wt-CD36, or mut-CD36 plasmid for 24 h, which had been treated with 400 μM OA during the final 6 h, then were fixed and stained with BODIPY FL-C16 (A) or ORO (E). Scale bars: 20 μm. The fluorescence signal intensity of FL-C16 per cell was quantified by ImageJ. Values were means ± SDs ( n = 50). (B) Cellular NEFA levels in cells subjected to the treatment shown in (A). (C and G) The EVA1A-knockdown cells were co-treated with 50 μM 2-BP and 400 μM OA for 6 h, then were subjected to BODIPY FL-C16 staining (C) or ORO staining (G). Scale bars: 20 μm. (D) Cellular NEFA levels in cells subjected to the treatment shown in (C). (F) Cellular TG contents in cells treated as described in (A). (H) Cellular TG contents in cells treated as described in (C). * P < 0.05, **P < 0.01, ***P < 0.001.

    Techniques Used: Inhibition, Knockdown, Transfection, Plasmid Preparation, Staining, Fluorescence



    Similar Products

    93
    MedChemExpress oa sangon
    EVA1A deletion promotes the palmitoylation of CD36. (A to C) The palmitoylation levels of CD36 were assessed using the APE assay after treatment <t>with</t> <t>2-BP</t> (50 μM, 6 h) as indicated, with or without HA. The top band indicated the palmitoylated CD36 (PEG-CD36). Detection of palmitoylated CD36 in EVA1A-knockdown HepG2 and Huh7 cells, along with control cells (A). Detection of palmitoylated CD36 in EVA1A-overexpressed HepG2 and Huh7 cells or control cells (B). Detection of palmitoylated CD36 in live tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3) (C). Protein levels of palmitoylated CD36 were quantified in the right panels. (D to G) Relative mRNA levels of genes related to palmitoyl transferases (Z DHHC4 and Z DHHC5 ) and acyl-protein thioesterase 1 ( LYPLA1 ) in vitro (D and E) and in vivo (F and G). (H) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in EVA1A-knockdown or overexpressed HepG2 and Huh7 cells, after 6-h treatment with 400 μM OA or after being left untreated. (I) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in liver tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3). Their protein levels were quantified in the lower panels. * P < 0.05, **P < 0.01, ***P < 0.001. HA: NH 2 OH.
    Oa Sangon, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oa sangon/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    oa sangon - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    EVA1A deletion promotes the palmitoylation of CD36. (A to C) The palmitoylation levels of CD36 were assessed using the APE assay after treatment with 2-BP (50 μM, 6 h) as indicated, with or without HA. The top band indicated the palmitoylated CD36 (PEG-CD36). Detection of palmitoylated CD36 in EVA1A-knockdown HepG2 and Huh7 cells, along with control cells (A). Detection of palmitoylated CD36 in EVA1A-overexpressed HepG2 and Huh7 cells or control cells (B). Detection of palmitoylated CD36 in live tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3) (C). Protein levels of palmitoylated CD36 were quantified in the right panels. (D to G) Relative mRNA levels of genes related to palmitoyl transferases (Z DHHC4 and Z DHHC5 ) and acyl-protein thioesterase 1 ( LYPLA1 ) in vitro (D and E) and in vivo (F and G). (H) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in EVA1A-knockdown or overexpressed HepG2 and Huh7 cells, after 6-h treatment with 400 μM OA or after being left untreated. (I) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in liver tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3). Their protein levels were quantified in the lower panels. * P < 0.05, **P < 0.01, ***P < 0.001. HA: NH 2 OH.

    Journal: Research

    Article Title: EVA1A Regulates Hepatic Lipid Homeostasis by Modulating CD36 Expression and Its Palmitoylation

    doi: 10.34133/research.1001

    Figure Lengend Snippet: EVA1A deletion promotes the palmitoylation of CD36. (A to C) The palmitoylation levels of CD36 were assessed using the APE assay after treatment with 2-BP (50 μM, 6 h) as indicated, with or without HA. The top band indicated the palmitoylated CD36 (PEG-CD36). Detection of palmitoylated CD36 in EVA1A-knockdown HepG2 and Huh7 cells, along with control cells (A). Detection of palmitoylated CD36 in EVA1A-overexpressed HepG2 and Huh7 cells or control cells (B). Detection of palmitoylated CD36 in live tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3) (C). Protein levels of palmitoylated CD36 were quantified in the right panels. (D to G) Relative mRNA levels of genes related to palmitoyl transferases (Z DHHC4 and Z DHHC5 ) and acyl-protein thioesterase 1 ( LYPLA1 ) in vitro (D and E) and in vivo (F and G). (H) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in EVA1A-knockdown or overexpressed HepG2 and Huh7 cells, after 6-h treatment with 400 μM OA or after being left untreated. (I) Western blot analysis of ZDHHC5, ZDHHC4, and APT1 in liver tissues of Eva1a +/+ mice and Eva1a −/− mice ( n = 3). Their protein levels were quantified in the lower panels. * P < 0.05, **P < 0.01, ***P < 0.001. HA: NH 2 OH.

    Article Snippet: For cell treatment, the final concentrations of OA (Sangon, China), 2-BP (MCE, USA), Torin-1 (Aladdin, China), and GW9662 (Aladdin, China) were 400 μM, 50 μM, 300 nM, and 5 μM, respectively.

    Techniques: Knockdown, Control, In Vitro, In Vivo, Western Blot

    Inhibition of CD36 palmitoylation attenuates EVA1A deficiency-induced fatty acid uptake and lipid droplet accumulation. (A and E) The EVA1A-knockdown HepG2 or Huh7 cells were transfected with empty vector (pcDNA3.1) or wt-CD36, or mut-CD36 plasmid for 24 h, which had been treated with 400 μM OA during the final 6 h, then were fixed and stained with BODIPY FL-C16 (A) or ORO (E). Scale bars: 20 μm. The fluorescence signal intensity of FL-C16 per cell was quantified by ImageJ. Values were means ± SDs ( n = 50). (B) Cellular NEFA levels in cells subjected to the treatment shown in (A). (C and G) The EVA1A-knockdown cells were co-treated with 50 μM 2-BP and 400 μM OA for 6 h, then were subjected to BODIPY FL-C16 staining (C) or ORO staining (G). Scale bars: 20 μm. (D) Cellular NEFA levels in cells subjected to the treatment shown in (C). (F) Cellular TG contents in cells treated as described in (A). (H) Cellular TG contents in cells treated as described in (C). * P < 0.05, **P < 0.01, ***P < 0.001.

    Journal: Research

    Article Title: EVA1A Regulates Hepatic Lipid Homeostasis by Modulating CD36 Expression and Its Palmitoylation

    doi: 10.34133/research.1001

    Figure Lengend Snippet: Inhibition of CD36 palmitoylation attenuates EVA1A deficiency-induced fatty acid uptake and lipid droplet accumulation. (A and E) The EVA1A-knockdown HepG2 or Huh7 cells were transfected with empty vector (pcDNA3.1) or wt-CD36, or mut-CD36 plasmid for 24 h, which had been treated with 400 μM OA during the final 6 h, then were fixed and stained with BODIPY FL-C16 (A) or ORO (E). Scale bars: 20 μm. The fluorescence signal intensity of FL-C16 per cell was quantified by ImageJ. Values were means ± SDs ( n = 50). (B) Cellular NEFA levels in cells subjected to the treatment shown in (A). (C and G) The EVA1A-knockdown cells were co-treated with 50 μM 2-BP and 400 μM OA for 6 h, then were subjected to BODIPY FL-C16 staining (C) or ORO staining (G). Scale bars: 20 μm. (D) Cellular NEFA levels in cells subjected to the treatment shown in (C). (F) Cellular TG contents in cells treated as described in (A). (H) Cellular TG contents in cells treated as described in (C). * P < 0.05, **P < 0.01, ***P < 0.001.

    Article Snippet: For cell treatment, the final concentrations of OA (Sangon, China), 2-BP (MCE, USA), Torin-1 (Aladdin, China), and GW9662 (Aladdin, China) were 400 μM, 50 μM, 300 nM, and 5 μM, respectively.

    Techniques: Inhibition, Knockdown, Transfection, Plasmid Preparation, Staining, Fluorescence